WATCH Sundrug Co.,Ltd. (9989.T)
Healthcare · Pharmaceutical Retailers · JPX · Japan
55
Final Score
-124.3%
Margin of Safety
65
Quality Score
¥3,709
Current Price
¥433.9B
Market Cap
Key Metrics
Pe Ratio
13.81
Forward Pe
13.52
Pb Ratio
1.52
Ev Ebitda
6.39
Roe
11.3%
Gross Margin
25.7%
Operating Margin
5.6%
Net Margin
3.7%
Dividend Yield
354.0%
Debt To Equity
16.75
Current Ratio
1.83
Beta
0.10
📈 Trend Charts
Revenue Trend
EPS Trend
Net Income Trend
Free Cash Flow Trend
Intrinsic Value Estimates
Low
¥1,323
Base
¥1,653
High
¥1,984
Pipeline Stage Details
Stage A — Hard Filters ✅
Pe Ratio
13.81
Eps Positive Years
4.00
Eps Lookback
4.00
Fcf Positive Years
4.00
Fcf Lookback
4.00
Debt To Equity
0.17
Current Ratio
1.83
Dilution Cagr
0.00
Stage B — Quality Score: 65/100
Stage C — Cyclicality: LOW
Normalized EPS
¥250.04
Stage F — Final Score Breakdown
| Component | Weighted Score |
|---|---|
| Valuation | 3.0 |
| Earnings Quality | 16.2 |
| Balance Sheet | 16.0 |
| Stability | 12.0 |
| Moat Proxies | 7.6 |
Top Drivers
- Adequate quality (score 65/100): meets minimum quality thresholds for the Graham-Buffett framework.
- Reasonable P/E of 13.8x — below long-run market average (~15-17x), suggesting the stock is not overpriced.
- Solid ROIC of 12.2% — above the 12% threshold, indicating the business creates genuine economic value for shareholders.
- Conservative leverage: D/E ratio of 0.17x is well within Graham's maximum of 1.0x, reducing insolvency risk.
- Low cyclicality: earnings are relatively stable and predictable, making intrinsic value estimates more reliable.
Top Risks
- No significant risks identified in this analysis.
Financial History
| Year | Revenue | Gross Profit | Operating Income | Net Income | EPS |
|---|---|---|---|---|---|
| 2023 | ¥690.5B | ¥171.9B | ¥37.5B | ¥25.7B | ¥219.82 |
| 2024 | ¥751.8B | ¥189.3B | ¥41.0B | ¥29.1B | ¥249.07 |
| 2025 | ¥801.8B | ¥204.1B | ¥44.5B | ¥30.8B | ¥262.91 |
| 2026 | ¥842.5B | ¥216.2B | ¥46.8B | ¥31.4B | ¥268.36 |
Cash Flow History
| Year | Operating CF | CapEx | Free Cash Flow |
|---|---|---|---|
| 2022 | N/A | N/A | N/A |
| 2023 | ¥37.4B | ¥-26.1B | ¥11.3B |
| 2024 | ¥41.2B | ¥-38.2B | ¥3.0B |
| 2025 | ¥41.2B | ¥-34.3B | ¥6.9B |
| 2026 | ¥43.3B | ¥-31.1B | ¥12.2B |